Transactions
-
October 2023
Advisory of:
in the addition of two biosimilar candidates of Denosumab from
-
October 2023
Advisory of:
in the $35mn series B growth investment into
-
July 2023
Advisory of:
in the acquisition of API developer and manufacturer
-
May 2023
Advisory of:
in the acquisition of the BioPharma Solutions business from
-
December 2021
Advisory of:
in the $11.7bn acquisition of
-
September 2021
Advisory of:
in the acquisition of leading complex API CDMO
-
July 2021
Advisory of:
in the acquisition of European pharmaceutical company
-
June 2021
Advisory of:
in the acquisition of manufacturing assets from
-
February 2021
Advisory of:
in the acquisition of sterile injectables manufacturer
-
February 2021
Advisory of:
in the acquisition of multiservice CDMO
-
January 2021
Advisory of:
in the acquisition of two lipid dose form sites from
-
July 2020
Advisory of:
in the acquisition of a majority stake in
-
April 2020
Advisory of:
in the growth investment into
-
September 2019
Advisory of:
in the acquisition of a 50% stake in
-
July 2019
Advisory of:
in the recapitalization of
-
April 2018
Advisory of:
in the €1.9bn acquisition of
-
December 2017
Sale of:
global CRO for radiolabeling services to
-
May 2016
Sale of:
Levothyroxine oral solution European rights to
-
April 2016
Advisory of:
in the acquisition of US specialty generics company
-
March 2016
Advisory of:
in the acquisition of Italian generics company
-
June 2015
Advisory of:
in the acquisition of a controlling equity stake in
-
March 2015
Advisory of:
in the acquisition of specialty API manufacturer
-
November 2013
Advisory of:
in the $2.6bn merger with
-
June 2012
Advisory of:
in partnering OTC Vitamin + Calcium Franchise to
-
October 2010
Advisory of:
in the sale of PulmoJet® DPI Franchise to
-
April 2009
Licensing of:
Phase 1 Hepatology Product by
-
April 2007
Licensing of:
Phase 1 Oncology Product by
-
September 2006
Licensing of:
Phase 1 Acute Cardiovascular Product by
-
August 2004
Sale of:
Phase 2 Dermatology Product to
